Alzheimer’s disease has a long history of breaking hearts and bending timelines. For years, “treatment” mostly meant “symptom management,” plus a lot of sticky notes, calendar alerts, and loved ones quietly becoming logistics superheroes. But in the last couple of years, something genuinely new happened in the U.S.: two FDA-approved medicines arrived that can slow Alzheimer’s progression for certain people.

Before we pop the confetti: these drugs do not cure Alzheimer’s, do not reverse memory loss, and are not for everyone. They’re more like a “slow the downhill roll” optionmost useful early in the disease, and only after careful testing and monitoring. Still, in a world where families are used to hearing “we can’t stop it,” even “we can slow it” is a meaningful change.

The Two FDA-Approved “Slow-Down” Drugs in Plain English

These medications belong to the same family: anti-amyloid monoclonal antibodies. Translation: lab-made proteins designed to latch onto forms of beta-amyloida protein that can clump into plaques in the brain, one hallmark of Alzheimer’s.

1) Leqembi (lecanemab)

Leqembi is approved to treat Alzheimer’s disease and is intended to be started in people with mild cognitive impairment (MCI) due to Alzheimer’s or mild Alzheimer’s dementiabasically, the earlier stages. It’s given by IV infusion, and it requires proof that amyloid is present (more on that in a second).

2) Kisunla (donanemab)

Kisunla is also FDA-approved for Alzheimer’s disease and is meant for treatment initiation in MCI or mild dementia stages. It’s given by IV infusion every four weeks, and one notable feature is that some patients may be able to stop after amyloid plaques are reduced to minimal levels on brain imaging (a “finite dosing” concept).

How These Drugs Work (and Why “Slowing” Is the Key Word)

Think of amyloid plaques like unwanted clutter. These drugs don’t magically redecorate the brain, but they help remove certain amyloid forms, and in clinical trials that was associated with slower decline on measures of thinking and day-to-day function.

Slower decline matters because Alzheimer’s isn’t one momentit’s a sequence of moments: handling bills, remembering appointments, cooking safely, recognizing medications, keeping track of conversations. If progression slows, people may get more time with their independence (or need less help for longer). The effect size isn’t huge, but it’s clinically meaningful for many families who measure life in “how many more good months can we preserve?” rather than “did a score move on a chart?”

Who Might Qualify (Spoiler: Not Everyone With Memory Problems)

These treatments are not for “anyone who’s forgetful.” They’re designed for people who likely have Alzheimer’s biology driving their symptomsand who are early enough in the disease course to match the studied populations.

Typical eligibility checklist

• Stage: Mild cognitive impairment due to Alzheimer’s or mild Alzheimer’s dementia (not moderate or severe stages).
• Evidence of amyloid: Confirmation of elevated beta-amyloid in the brain using testing such as amyloid PET imaging, cerebrospinal fluid (CSF) tests, and increasingly, FDA-cleared blood tests that help identify amyloid-related pathology.
• Brain safety screen: A baseline MRI to look for bleeding risk markers (like microhemorrhages or superficial siderosis) and other issues that would raise concern.
• Medical fit: A clinician reviews meds and conditionsespecially blood thinners/antithromboticsbecause bleeding risk is a real consideration.

If that sounds like a lot, it is. But it’s not “red tape for fun.” It’s because the biggest risk with these drugs isn’t a nuisance side effect like dry mouth. It’s a brain imaging abnormality that can look like a stroke.

What the Benefits Look Like (Numbers Without the Headache)

Clinical trials used standardized measures such as the Clinical Dementia Rating–Sum of Boxes (CDR-SB) and other composite scores. Here’s the big-picture takeaway:

• Lecanemab (Leqembi): In a major 18-month trial, participants had moderately less decline on cognition and function measures compared with placebo. This is often described as a slowing of decline rather than improvement.
• Donanemab (Kisunla): In a phase 3 trial over about 76 weeks, donanemab showed significant slowing of clinical decline compared with placebo on key outcomes (including CDR-SB and iADRS), with results varying by underlying tau burden and study population definitions.

Important nuance: “Average benefit” doesn’t predict exactly what any one person will experience. Some may feel a meaningful difference in daily life; some may not notice much; some may stop early due to side effects. That’s why shared decision-making is everything here.

The Biggest Risk: ARIA (Yes, You Need to Know This Acronym)

Both Leqembi and Kisunla carry a boxed warning about ARIAamyloid-related imaging abnormalities. ARIA can show up as:

• ARIA-E: swelling/edema (often temporary)
• ARIA-H: bleeding (microhemorrhages or, rarely, larger hemorrhages)

Many ARIA cases are asymptomatic and found only on scheduled MRI scans. But symptoms can occur, including headache, confusion, dizziness, vision changes, difficulty walking, nausea, or seizures. In rare cases, ARIA can be serious or fatal, which is why MRI monitoring is built into treatment protocols.

Why APOE ε4 matters

People with certain geneticsparticularly APOE ε4 homozygotes (two copies)have a higher risk of ARIA. Many clinicians recommend (or strongly consider) APOE testing before starting treatment so patients can make a fully informed decision about risk.

What Treatment Actually Involves (The “Real Life” Part)

This is where many people’s expectations get gently corrected. These aren’t quick prescriptions you grab with shampoo and a greeting card.

Leqembi: the cadence

• How it’s given: IV infusion (commonly every 2 weeks initially)
• Monitoring: baseline MRI plus additional MRIs at specific points, with extra imaging if symptoms suggest ARIA
• Clinic time: infusion visit + monitoring + follow-up appointments

Kisunla: the cadence

• How it’s given: IV infusion every 4 weeks (monthly)
• Monitoring: baseline MRI and additional MRIs before several early infusions (because ARIA tends to happen early)
• Potential finite dosing: clinicians may consider stopping if amyloid plaques fall to minimal levels on amyloid PET imaging

In both cases, treatment is most safely delivered in a system that can coordinate:

• memory specialists or neurologists
• infusion centers
• MRI scheduling and urgent follow-up if symptoms appear
• caregiver support (because logistics are part of the “treatment plan”)

Costs, Coverage, and the Medicare Reality Check

These therapies are expensive and resource-intensive. In the U.S., coverage has evolved, especially for Medicare beneficiaries. Broadly speaking, Medicare coverage for FDA-approved anti-amyloid antibodies has been tied to Coverage with Evidence Developmentmeaning participation in a registry or data collection program can be part of access, alongside meeting clinical criteria (early-stage diagnosis and appropriate clinical oversight).

This can feel frustrating until you remember what Medicare is trying to answer: “How do these drugs perform in the messy, real worldoutside the controlled environment of clinical trials?” Registries help track safety events, outcomes, and patient selection, which can improve care pathways over time.

So… Should Everyone With Early Alzheimer’s Get One?

Not automatically. A more useful question is:

“Given my stage, my brain imaging, my medications, my genetic risk, and my personal valuesdoes the potential benefit outweigh the risk and burden?”

Some people will say, “I’ll take every safe month I can get.” Others will say, “The MRI schedule alone will wreck my quality of life.” Both are valid. What’s new is that patients now have a real choice to consider.

Frequently Asked Questions

Do these drugs work for moderate or advanced Alzheimer’s?

No. The evidence and FDA labeling focus on starting treatment in mild cognitive impairment or mild dementia stages. Starting later hasn’t been proven safe or effective in the same way.

Will my loved one “get better” on these medications?

Most people should not expect dramatic improvement. Think “slower worsening,” not “rewind button.” Some patients may feel stable for a while; others may still decline, just more slowly.

Why do we need proof of amyloid?

Because these drugs target amyloid biology. If memory symptoms are due to something elseor if amyloid isn’t elevatedbenefit is unlikely, and risk is still real.

Are infusions safe for older adults?

They can be, but safety depends on the individual. Age alone isn’t the deciding factor; brain MRI findings, medication use (especially blood thinners), and overall health matter a lot.

Conclusion: A New Era, With Fine Print (But Still a Big Deal)

For the first time, many U.S. patients with early Alzheimer’s can discuss FDA-approved drugs that may slow progressionnot just treat symptoms. That’s a genuine shift. It’s also a commitment: testing, infusions, MRI monitoring, and careful risk management.

If you’re a patient or caregiver, ask a memory specialist about eligibility and safety. If you’re a clinician, these drugs are a call to build (or strengthen) treatment pathways that blend neurology, imaging, infusion services, and shared decision-making. If you’re a friend or family member, your role matters more than you thinksometimes “treatment” starts with someone showing up to help coordinate the next appointment.

Experiences From the Real World (What It’s Like Around These Treatments)

Let’s talk about the part that never fits neatly into a prescribing label: the lived experience. Not “miracle stories,” not doomscrolling eitherjust what families and care teams often encounter when they explore or start these therapies.

First comes the emotional whiplash. Many patients arrive at a memory clinic expecting either a definitive cure or a definitive dead end. Being told, “We can slow this, but it’s complicated,” can feel oddly disorienting. Hope shows upbut it’s hope with homework. There are appointments for cognitive testing, biomarker confirmation, baseline MRI, and sometimes genetic counseling for APOE status. Families often describe this phase as “learning a new language,” where acronyms (MCI, PET, ARIA) multiply like rabbits.

Then comes the logistics reality. Infusions sound manageable until you do the math: travel time, time off work for a care partner, scheduling, and the mental overhead of “Did we book the MRI before the next infusion?” Some caregivers say the routine becomes a strange kind of structureannoying, but also grounding, because it turns Alzheimer’s from a vague threat into a plan with steps. Others find it exhausting, especially in rural areas where imaging and infusion capacity can be limited.

Side effect vigilance becomes a team sport. In real-world settings, the biggest anxiety often isn’t the infusion itselfit’s “What if symptoms happen at home?” Families frequently keep a short list on the fridge: severe headache, confusion, vision changes, trouble walking, seizure-like symptoms. Not because they’re expecting disaster, but because being prepared reduces panic. Clinicians often coach caregivers to trust their instincts: if something feels “off” beyond normal bad days, call.

Patients measure success differently than trials do. A clinical trial tracks a score change. A family tracks whether Dad can still cook eggs without leaving the stove on, whether Mom can still follow a conversation at dinner, whether bills get paid without a crisis. Some caregivers report that the most valuable outcome is not a sudden improvement, but a slower accumulation of “small losses.” When progression slows, it can mean more time for meaningful conversations, more time for independence, and more time to plan ahead while the patient can still participate.

Shared decision-making is not a buzzword hereit’s survival. Some people start therapy and feel relief: “We’re doing something.” Others decide against it and feel relief: “We’re protecting quality of life.” Many clinics now frame it as a values-based choice: How do you weigh a modest slowing benefit against MRI monitoring, infusion visits, and ARIA risk? What’s your tolerance for uncertainty? How important is independence vs. minimizing medicalization? These are intensely personal questions, and the “right” decision can be different even within the same family.

Finally, the experience often changes relationships. Caregivers can feel more empoweredbecause there’s a plan and a team. They can also feel more pressurebecause the plan is complex. Patients sometimes feel proud to be “fighting back,” and sometimes feel overwhelmed by becoming a patient in a system. The best real-world outcomes tend to happen when clinics offer not just infusions, but support: clear education, written symptom checklists, predictable MRI schedules, and a point of contact who answers questions without making people feel like they’re bothering anyone.

If there’s one consistent theme, it’s this: these drugs don’t just treat a diseasethey reshape the care journey. For many families, that reshaping is worth it. For others, it isn’t. But either way, the fact that the conversation now includes “slowing Alzheimer’s” is something past generations didn’t get to discuss.

The post There May Be Two FDA-Approved Medication to Slow Alzheimer’s Disease appeared first on Global Travel Notes.